

DEX - 0271



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

BB

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 51/00, 39/395, C12Q 1/00, 1/68, G01N 33/53, C07K 1/00, 16/00		A1	(11) International Publication Number: WO 00/07632 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/US99/16357 (22) International Filing Date: 20 July 1999 (20.07.99)		(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).	
(30) Priority Data: 60/095,231 4 August 1998 (04.08.98) US		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/095,231 (CIP) Filed on 4 August 1998 (04.08.98)		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SUN, Yongming [CN/CN]; Apartment 260, 869 Winchester Boulevard, San Jose, CA 95128 (US). RECIPON, Herve [FR/FR]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). MACINA, Roberto, A. [AR/AR]; 4118 Crescendo Avenue, San Jose, CA 95136 (US).			
(54) Title: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING COLON CANCER			
(57) Abstract The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating colon cancer.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

A NOVEL METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING COLON CANCER

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating cancers, particularly
colon cancer.

BACKGROUND OF THE INVENTION

10 Cancer of the colon is a highly treatable and often
curable disease when localized to the bowel. It is one of the
most frequently diagnosed malignancy in the United States as
well as the second most common cause of cancer death. Surgery
is the primary treatment and results in cure in approximately
15 50% of patients. However, recurrence following surgery is a
major problem and often is the ultimate cause of death.

The prognosis of colon cancer is clearly related to the
degree of penetration of the tumor through the bowel wall and
the presence or absence of nodal involvement. These two
20 characteristics form the basis for all staging systems
developed for this disease. Treatment decisions are usually
made in reference to the older Duke's or the Modified Astler-
Coller (MAC) classification scheme for staging.

Bowel obstruction and bowel perforation are indicators
25 of poor prognosis in patients with colon cancer. Elevated
pretreatment serum levels of carcinoembryonic antigen (CEA)
and of carbohydrate antigen 19-9 (CA 19-9) also have a
negative prognostic significance.

Age greater than 70 years at presentation is not a
30 contraindication to standard therapies. Acceptable morbidity
and mortality, as well as long-term survival, are achieved in
this patient population.

- 2 -

Because of the frequency of the disease (approximately 160,000 new cases of colon and rectal cancer per year), the identification of high-risk groups, the demonstrated slow growth of primary lesions, the better survival of early-stage 5 lesions, and the relative simplicity and accuracy of screening tests, screening for colon cancer should be a part of routine care for all adults starting at age 50, especially those with first-degree relatives with colorectal cancer.

Procedures used for detecting, diagnosing, monitoring, 10 staging, and prognosticating colon cancer are of critical importance to the outcome of the patient. For example, patients diagnosed with early colon cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized 15 colon cancer. New diagnostic methods which are more sensitive and specific for detecting early colon cancer are clearly needed.

Colon cancer patients are closely monitored following initial therapy and during adjuvant therapy to determine 20 response to therapy and to detect persistent or recurrent disease of metastasis. There is clearly a need for a colon cancer marker which is more sensitive and specific in detecting colon cancer, its recurrence, and progression.

Another important step in managing colon cancer is to 25 determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of colon cancer is preferable over clinical staging because the former gives a more accurate 30 prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of colon cancer would be improved by detecting new markers in cells, tissues, or bodily

- 3 -

fluids which could differentiate between different stages of invasion.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, 5 *in vivo* imaging and treating colon cancer via three (3) Colon Specific Genes (CSGs). The 3 CSGs refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, or 3. In the alternative, what is meant by the 3 CSGs as used herein, 10 means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, or 3 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, or 3.

Other objects, features, advantages and aspects of the 15 present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various 20 changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

25 Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of colon cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid 30 type of a normal human control, wherein an increase in levels of CSG in the patient versus normal human control is associated with colon cancer.

Further provided is a method of diagnosing metastatic colon cancer in a patient having such cancer which is not

- 4 -

known to have metastasized by identifying a human patient suspected of having colon cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, 5 tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

10 Also provided by the invention is a method of staging colon cancer in a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing CSG levels in such cells, tissues, or bodily fluid 15 with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a 20 cancer which is regressing or in remission.

Further provided is a method of monitoring colon cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically 25 analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the 30 patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change in stage of colon cancer in a human having such cancer by looking at levels of CSG in a human having such cancer. The 35 method comprises identifying a human patient having such

- 5 -

cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid

5 type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

10 Further provided are antibodies against the CSGs or fragments of such antibodies which can be used to detect or image localization of the CSGs in a patient for the purpose of detecting or diagnosing a disease or condition. Such antibodies can be polyclonal or monoclonal, or prepared by

15 molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art.

20 Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a CSG. In therapeutic

25 applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in

30 the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the

35 disclosed invention will become readily apparent to those

- 6 -

skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, and prognosticating cancers by comparing levels of CSG with those of CSG in a normal human control. What is meant by levels of CSG as used herein, means levels of the native protein expressed by the genes comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, or 3. In the alternative, what is meant by levels of CSG as used herein, means levels of the native mRNA encoded by any of the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, or 3 or levels of the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, or 3. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of any one of the CSG proteins compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including colon cancer. Any of the 3 CSGs may be measured alone in the methods of the invention, or all together or any combination of the three.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

30

Diagnostic Assays

The present invention provides methods for diagnosing the presence of colon cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels

- 7 -

of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of CSG in the patient versus the normal human control is associated with the presence of colon cancer.

5 Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferable are 10 at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic colon cancer in a patient having colon cancer which has not yet metastasized for the onset of 15 metastasis. In the method of the present invention, a human cancer patient suspected of having colon cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For 20 example, in the case of colon cancer, patients are typically diagnosed with colon cancer following traditional detection methods.

In the present invention, determining the presence of CSG level in cells, tissues, or bodily fluid, is particularly 25 useful for discriminating between colon cancer which has not metastasized and colon cancer which has metastasized. Existing techniques have difficulty discriminating between colon cancer which has metastasized and colon cancer which has not metastasized and proper treatment selection is often 30 dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues, or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That 35 is, if the cancer marker being observed is just CSG in serum,

- 8 -

this level is preferably compared with the level of CSG in serum of a normal human patient. An increase in the CSG in the patient versus the normal human control is associated with colon cancer which has metastasized.

5 Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as CSG, are at least two 10 times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the 15 patient; in the methods for diagnosing metastasis or monitoring for metastasis, normal human control preferably includes samples from a human patient that is determined by reliable methods to have colon cancer which has not metastasized such as earlier samples from the same patient 20 prior to metastasis.

Staging

The invention also provides a method of staging colon cancer in a human patient.

The method comprises identifying a human patient having 25 such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG. Then, the method compares CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in 30 CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

- 9 -

Monitoring

Further provided is a method of monitoring colon cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such 5 cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human 10 control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this inventions is a method of monitoring the change in stage of colon cancer in a human 15 having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, 20 tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage 25 or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

30 Assay Techniques

Assay techniques that can be used to determine levels of gene expression, such as CSG of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays,

- 10 -

reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches. Among these, ELISAs are 5 frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a 10 reporter antibody generally is prepared which binds specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

15 To carry out the ELISA, antibody specific to CSG is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be 20 analyzed is incubated in the dish, during which time CSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the 25 reporter antibody to any monoclonal antibody bound to CSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount 30 of color developed in a given time period is proportional to the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies 35 specific to CSG attached to a solid support and labeled CSG

- 11 -

and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods may be used to detect CSG mRNA as
5 a marker for colon cancer. Polymerase chain reaction (PCR)
and other nucleic acid methods, such as ligase chain reaction
(LCR) and nucleic acid sequence based amplification (NASABA),
can be used to detect malignant cells for diagnosis and
monitoring of various malignancies. For example, reverse-
10 transcriptase PCR (RT-PCR) is a powerful technique which can
be used to detect the presence of a specific mRNA population
in a complex mixture of thousands of other mRNA species. In
RT-PCR, an mRNA species is first reverse transcribed to
complementary DNA (cDNA) with use of the enzyme reverse
15 transcriptase; the cDNA is then amplified as in a standard PCR
reaction. RT-PCR can thus reveal by amplification the
presence of a single species of mRNA. Accordingly, if the
mRNA is highly specific for the cell that produces it, RT-PCR
can be used to identify the presence of a specific type of
20 cell.

Hybridization to clones or oligonucleotides arrayed on
a solid support (i.e., gridding) can be used to both detect
the expression of and quantitate the level of expression of
that gene. In this approach, a cDNA encoding the CSG gene
25 is fixed to a substrate. The substrate may be of any suitable
type including but not limited to glass, nitrocellulose, nylon
or plastic. At least a portion of the DNA encoding the CSG
gene is attached to the substrate and then incubated with the
analyte, which may be RNA or a complementary DNA (cDNA) copy
30 of the RNA, isolated from the tissue of interest.
Hybridization between the substrate bound DNA and the analyte
can be detected and quantitated by several means including but
not limited to radioactive labeling or fluorescence labeling
of the analyte or a secondary molecule designed to detect the
35 hybrid. Quantitation of the level of gene expression can be

- 12 -

done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that
5 material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by
10 different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the
15 first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot.
20 Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived
25 from a variety of patients' cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) such as from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can
30 include whole blood, plasma, serum, or any derivative of blood.

In Vivo Antibody Use

Antibodies against CSG can also be used *in vivo* in patients with diseases of the colon. Specifically, antibodies

- 13 -

against an CSG can be injected into a patient suspected of having a disease of the colon for diagnostic and/or therapeutic purposes. The use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-5 chelators labeled with Indium-111 have been described for use in the radioimmunoscinographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of 10 having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSGs can be used in 15 a similar manner. Labeled antibodies against an CSG can be injected into patients suspected of having a disease of the colon such as colon cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to 20 be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium 25 (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label within the colon or external to the colon permits determination of the spread of the disease. The amount of label within the colon also allows determination of the presence or absence of cancer in the 30 colon.

For patients diagnosed with colon cancer, injection of an antibody against a CSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent 35 such as a drug, toxin or radionuclide to enhance its

- 14 -

therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, *Cancer Research* 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various 5 cancers has also been described by Pastan et al. *Cell* 1986 47:641-648). Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares *Cancer Supplement* 1997 80:2675-2680). Other cytotoxic 10 radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against CSGs.

Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and 15 antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

20 EXAMPLES

The present invention is further described by the following example. The example is provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific 25 aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

Example 1

Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte 30 Pharmaceuticals, Palo Alto, CA, using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

- 15 -

The CLASP performs the following steps:

Selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus all the other organs.

5 Analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease.

Selection of the candidates demonstrating component ESTs were exclusively or more frequently found in tumor libraries.

10 CLASP allows the identification of highly expressed organ and cancer specific genes useful in the diagnosis of colon cancer.

Table 1: CSGs Sequences

	SEQ ID NO:	LS Clone ID	LSA Gene ID
15	1	1517021	236347
	2	776410	202109
	3	611082	202298

The following Example was carried out using standard techniques, which are well known and routine to those of skill 20 in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory 25 Press, Cold Spring Harbor, N.Y. (1989).

Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclelease activity of Taq DNA polymerase. The method uses an 30 internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected

- 16 -

by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control was used to standardize the amount of sample RNA added to the reaction and 5 normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) was used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were 10 used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene 15 was evaluated for every example in normal and cancer tissue. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was 20 done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

25 Comparative Examples

Similar mRNA expression analysis for genes coding for the diagnostic markers PSA (Prostate Specific Antigen) and PLA2 (Phospholipase A2) was performed for comparison. PSA is the only cancer screening marker available in clinical 30 laboratories. When the panel of normal pooled tissues was analyzed, PSA was expressed at very high levels in prostate, with a very low expression in breast and testis. After more than 55 matching samples from 14 different tissues were analyzed, the data corroborated the tissue specificity seen 35 with normal tissue samples. PSA expression was compared in

- 17 -

cancer and normal adjacent tissue for 12 matching samples of prostate tissue. The relative levels of PSA were higher in 10 cancer samples (83%). Clinical data recently obtained support the utilization of PLA2 as a staging marker for late 5 stages of prostate cancer. mRNA expression data showed overexpression of the mRNA in 8 out of the 12 prostate matching samples analyzed (66%). The tissue specificity for PLA2 was not as good as the one described for PSA. In addition to prostate, also small intestine, liver, and 10 pancreas showed high levels of mRNA expression for PLA2.

**Measurement of SEQ ID NO: 1; Clone ID1517021; Gene ID236347
(Cln117)**

The absolute numbers shown in Table 2 are relative levels of expression of Cln117 in 12 normal different tissues. All 15 the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 2: Relative levels of Cln117 Expression in Pooled
20 Samples**

Tissue	NORMAL
Colon-Ascending	238
Endometrium	0
Kidney	0.02
Liver	0
Ovary	0.23
Pancreas	0
Prostate	0.06
Small Intestine	35
Spleen	0.0
Stomach	16
Testis	1
Uterus	0.06

The relative levels of expression in Table 2 show that Cln117 35 mRNA expression is higher (238) in colon compared with all the other normal tissues analyzed. Small intestine, with a relative expression level of 35, and stomach with 16 are the

- 18 -

only other tissues expressing mRNA for Cln117. These results establish that Cln117 mRNA expression is highly specific for tissues from the digestive system.

The absolute numbers in Table 2 were obtained analyzing 5 pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative 10 levels of expression of Cln117 in 75 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

15 Table 3: Relative levels of Cln117 Expression in Individual Samples

	Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
20	Sto AC93		Stomach 1	94	189
	Sto AC99		Stomach 2	21	30
	Sto 539S		Stomach 3	3	4
	Sto 728A		Stomach 4	0.11	2
25	Sto AC44		Stomach 5	20	28
	Sto MT54		Stomach 6	58	14
	Sto TA73		Stomach 7	88	102
	Sto 288S		Stomach 8	44	2
	SmI H89		Sm. Int. 1	101	167
	SmI 21XA		Sm. Int. 2	62	15
30	Cln AS45	Adenocarcinoma Duke's Stage A	Colon- Ascending 1	45	57
	Cln CM67	Adenocarcinoma Duke's Stage B	Colon-Cecum 2	44	37

- 19 -

	Cln AS67	Adenocarcinoma Duke's Stage B	Colon- Ascending 3	97	40
	Cln AS43	Adenocarcinoma Duke's Stage C	Colon- Ascending 4	143	39
	Cln AS46	Adenocarcinoma Duke's Stage C	Colon Ascending 5	214	182
	Cln AS98	Adenocarcinoma Duke's Stage C	Colon- Ascending 6	189	106
5	Cln B56	Adenocarcinoma Duke's Stage C	Colon-Cecum 7	89	143
	Cln AS89	Adenocarcinoma Duke's Stage D	Colon- Ascending 8	45	10
	Cln TX01	Adenocarcinoma Duke's Stage B	Colon- Transverse 9	20	42
	Cln TX89	Adenocarcinoma Duke's Stage B	Colon- Transverse 10	32	17
	Cln TX67	Adenocarcinoma Duke's Stage C	Colon- Transverse 11	23	30
	Cln MT38	Adenocarcinoma Duke's Stage D	Colon-Splenic flexure 12	87	82
10	Cln SG36	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 13	173	144
	Cln SG27	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 14	79	76
	Cln SG89	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 15	57	56
	Cln SG67	Adenocarcinoma Duke's Stage C	Colon-Sigmoid 16	20	19
	Cln SG33	Adenocarcinoma Duke's Stage C	Colon-Sigmoid 17	125	223
	Cln SG45	Adenocarcinoma Duke's Stage D	Colon-Sigmoid 18	62	48
15	Cln B34	Adenocarcinoma Duke's Stage A	Colon- Rectosigmoid 19	37	11
	Cln CXGA	Adenocarcinoma Duke's Stage A	Colon-Rectum 20	201	136
	Cln RC67	Adenocarcinoma Duke's Stage B	Colon-Rectum 21	15	52

- 20 -

	Cln SG98	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 22	40	58
	Cln C9XR	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 23	22	27
	Cln RS45	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 24	269	112
	Cln RC01	Adenocarcinoma Duke's Stage C	Colon-Rectum 25	19	62
5	Cln RC89	Adenocarcinoma Duke's Stage D	Colon-Rectum 26	0.36	44
	Cln RC24	Adenocarcinoma Duke's Stage D	Colon-Rectum 27	91	77
	Bld 32XK		Bladder 1	0.82	0
	Bld 46XK		Bladder 2	0	0.25
	Bld 66X		Bladder 3	0.35	0
10	Cvx NKS54		Cervix 1	0.31	0
	Cvx KS52		Cervix 2	0	0
	Cvx NK24		Cervix 3	0.23	0
	End 4XA		Endometrium 1	0	0
15	End 8911		Endometrium 2	0.04	1.24
	End 8XA		Endometrium 3	0.08	4
	Kid 5XD		Kidney 1	0.92	1.67
	Kid 6XD		Kidney 2	0.30	0.02
20	Kid 106XD		Kidney 3	0	0.06
	Kid 126XD		Kidney 4	0	0
	Kid 12XD		Kidney 5	0	0
	Liv 42X		Liver 1	50	0
25	Liv 15XA		Liver 2	16	0.19
	Liv 94XA		Liver 3	0.37	0.04

- 21 -

	Lng AC69	Lung 1	0.41	0
	Lng BR94	Lung 2	0.05	0
	Lng 47XQ	Lung 3	0	0
	Lng 90X	Lung 4	0	0
5	Mam 59X	Mammary Gland 1	0	0
	Mam 12X	Mammary Gland 2	0	0
	Mam B011X	Mammary Gland 3	0	0
	Mam A06X	Mammary Gland 4	0.02	0
10	Ovr 103X	Ovary 1	0.01	0.021
	Pan 71XL	Pancreas 1	114.56	123
	Pan 77X	Pancreas 2	0.18	0.09
	Pan 92X	Pancreas 3	146	0.30
15	Pan 82XP	Pancreas 4	0.02	0
	Pro 109XB	Prostate 1	0	0.01
	Pro 34B	Prostate 2	0	0.03
	Pro 12B	Prostate 3	0	0
20	Pro 23B	Prostate 4	0	0.05
	Tst 39X	Testis 1	1.60	0.60
	Utr 85XU	Uterus 1	0.21	0
	Utr 141XO	Uterus 2	1.80	0
25	Utr 23XU	Uterus 3	1.36	0.07
	0=negative			

In the analysis of matching samples, the higher levels of expression were in colon, showing a high degree of tissue specificity for digestive system. Of all the samples different than colon analyzed, only four samples (the cancer samples for the matches of liver 1 and 2, and pancreas 1 and 3; and the normal adjacent for the pancreas match #1) showed

- 22 -

an expression comparable to the mRNA expression in colon. These results confirm the tissue specificity results obtained with the panel of normal pooled samples (Table 2).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Cln117 in 17 primary colon cancer tissues compared with their respective normal adjacent (colon samples #2, 3, 4, 5, 6, 8, 10, 12, 13, 14, 15, 16, 18, 19, 20, 24, and 27). There was overexpression in the cancer tissue for 63% of the colon matching samples tested (total of 27 colon matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 63% of the primary colon matching samples tested is demonstrative of Cln117 being a diagnostic marker for colon cancer.

Measurement of SEQ ID NO:2; Clone ID776410; Gene ID202109
20 (Cln124)

The absolute numbers depicted in Table 4 are relative levels of expression of Cln124 in 12 normal different tissues. All the values are compared to normal colon (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 4: Relative levels of Cln124 Expression in Pooled Samples

Tissue	NORMAL
Colon-Ascending	10000
Endometrium	0
Kidney	0.2
Liver	0
Ovary	0
Pancreas	0
Prostate	0.3
Small Intestine	6

- 23 -

Spleen	2
Stomach	0
Testis	1
Uterus	0

5 The relative levels of expression in Table 4 show that Cln124 mRNA expression is more than 1000 fold higher in the pool of normal colon (10000) compared to all the other tissues analyzed. These results demonstrate that Cln124 mRNA expression is highly specific for colon.

10 The absolute numbers in Table 4 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 5.

15 The absolute numbers depicted in Table 5 are relative levels of expression of Cln124 in 41 pairs of matching samples. All the values are compared to normal colon (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal 20 adjacent sample for that same tissue from the same individual.

Table 5: Relative levels of Cln124 Expression in Individual Samples

	Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
25	Sto MT54		Stomach 1	0	0
	SmI 21XA		Sm. Int. 1	0	0
	Cln AS45	Adenocarcinoma Duke's Stage A	Colon- Ascending 1	0.03	0.15
	Cln CM67	Adenocarcinoma Duke's Stage B	Colon-Cecum 2	0.37	2.06
	Cln AS12	Adenocarcinoma Duke's Stage B	Colon- Ascending 3	0.40	5.20
30	Cln AS43	Adenocarcinoma Duke's Stage C	Colon- Ascending 4	0	0.10

- 24 -

	Cln AS46	Adenocarcinoma Duke's Stage C	Colon Ascending 5	0.02	1.73
	Cln AS98	Adenocarcinoma Duke's Stage C	Colon- Ascending 6	0.17	1.58
	Cln AC19	Adenocarcinoma Duke's Stage D	Colon- Ascending 7	0.59	7.05
	Cln TX01	Adenocarcinoma Duke's Stage B	Colon- Transverse 8	0	1.53
5	Cln MT38	Adenocarcinoma Duke's Stage D	Colon-Splenic flexture 9	0.001	2.43
	Cln DC19	Adenocarcinoma Duke's Stage B	Colon- Descending 10	0.41	1.34
	Cln DC63	Adenocarcinoma Duke's Stage C	Colon- Descending 11	0.005	0.50
	Cln DC22	Adenocarcinoma Duke's Stage D	Colon- Descending 12	0.002	0.09
	Cln SG36	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 13	0.03	0.81
	Cln SG20	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 14	0	1.64
	Cln SG27	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 15	0.11	1.04
10	Cln SG89	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 16	0.11	1.07
	Cln SG66	Adenocarcinoma Duke's Stage C	Colon-Sigmoid 17	0	0.45
	Cln SG67	Adenocarcinoma Duke's Stage C	Colon-Sigmoid 18	0.02	0.04
	Cln SG33	Adenocarcinoma Duke's Stage C	Colon-Sigmoid 19	0.03	1.00
	Cln CXGA	Adenocarcinoma Duke's Stage A	Colon-Rectum 20	0.34	2.36
15	Cln RC24	Adenocarcinoma Duke's Stage B	Colon-Rectum 21	0.86	1.64
	Cln RS86	Adenocarcinoma Duke's Stage B	Colon- Rectosigmoid 22	0.01	0.97

- 25 -

	Cln RS16	Adenocarcinoma Duke's Stage B	Colon- Rectosigmoid 23	0.01	0.05
	Cln SG98	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 24	0.43	2.77
	Cln C9XR	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 25	0.01	0.35
	Cln RS53	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 26	0.01	1.60
5	Cln RS45	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 27	0.23	0.54
	Cln RC24	Adenocarcinoma Duke's Stage D	Colon-Rectum 28	0.86	1.64
	Bld 32XK		Bladder 1	0	0
	Cvx KS52		Cervix 1	0	0
10	End 10479		Endometrium 1	0	0
	Kid 109XD		Kidney 1	0	0
	Kid 107XD		Kidney 2	0	0
15	Kid 106XD		Kidney 3	0	0
	Liv 15XA		Liver 1	0	0
	Lng 47XQ		Lung 1	0	0
	Mam 12X		Mammary Gland 1	0	0
20	Tst 39X		Testis 1	0	0
	Utr 85XU		Uterus 1	0	0

0=negative

In the analysis of matching samples, the higher levels of expression were in colon showing a high degree of tissue specificity for colon tissue. These results confirm the

- 26 -

tissue specificity results obtained with normal pooled samples (Table 4).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. lower levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 5 shows reduction of expression of Cln124 in 28 primary colon cancer samples compared with their respective normal adjacent. There is downregulation of Cln124 in the cancer tissue for all the colon matching samples tested (total of 28 primary colon matching samples).

Altogether, the high level of tissue specificity, plus the mRNA downregulation in 100% of the colon matching samples tested are demonstrative of Cln124 being a diagnostic marker for colon cancer.

Measurement of SEQ ID NO:3; Clone ID611082; Gene ID202298
(Cln125)

The absolute numbers depicted in Table 6 are relative levels of expression of Cln125 in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

25 Table 6: Relative levels of Cln125 Expression in Pooled Samples

30

35

Tissue	NORMAL
Colon-Ascending	2486
Endometrium	0.8
Kidney	0
Liver	0
Ovary	1.3
Pancreas	0
Prostate	0
Small Intestine	0
Spleen	0
Stomach	0.5

- 27 -

Testis	1
Uterus	0

The relative levels of expression in Table 6 show that Cln125 mRNA expression is higher (2486) in colon compared with 5 all the other normal tissues analyzed. Ovary, with a relative expression level of 1.3, endometrium (0.8), and stomach (0.5) are the only other tissues expressing mRNA for Cln125. These results established that Cln125 mRNA expression is highly specific for colon.

10 The absolute numbers in Table 6 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 7.

15 The absolute numbers depicted in Table 7 are relative levels of expression of Cln125 in 75 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal 20 adjacent sample for that same tissue from the same individual.

Table 7: Relative levels of Cln125 Expression in Individual Samples

	Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
25	Sto AC93		Stomach 1	1	2
	Sto AC99		Stomach 2	0	0
	Sto 539S		Stomach 3	0	0
	Sto 728A		Stomach 4	0	0
	Sto AC44		Stomach 5	0	0
	Sto MT54		Stomach 6	3	0
	Sto TA73		Stomach 7	0	0
	Sto 288S		Stomach 8	0	0
	SmI H89		Sm. Int. 1	0	0.5

	SmI 21XA		Sm. Int. 2	1	0
	Cln CM67	Adenocarcinoma Duke's Stage B	Colon-Cecum 1	3	27
	Cln AS12	Adenocarcinoma Duke's Stage B	Colon- Ascending 2	106	1290
	Cln AS43	Adenocarcinoma Duke's Stage C	Colon- Ascending 3	0	131
5	Cln AS46	Adenocarcinoma Duke's Stage C	Colon Ascending 4	0	461
	Cln AS98	Adenocarcinoma Duke's Stage C	Colon- Ascending 5	376	558
	Cln B56	Adenocarcinoma Duke's Stage C	Colon-Cecum 6	32	572
	Cln AS89	Adenocarcinoma Duke's Stage D	Colon- Ascending 7	3	0
	Cln AC19	Adenocarcinoma Duke's Stage D	Colon- Ascending 8	2	603
10	Cln TX01	Adenocarcinoma Duke's Stage B	Colon- Transverse 9	1	525
	Cln TX89	Adenocarcinoma Duke's Stage B	Colon- Transverse 10	5	401
	Cln TX67	Adenocarcinoma Duke's Stage C	Colon- Transverse 11	0	717
	Cln MT38	Adenocarcinoma Duke's Stage D	Colon-Splenic flexture 12	3	1562
	Cln SG36	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 13	3	1073
15	Cln SG20	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 14	2	1021
	Cln SG27	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 15	207	951
	Cln SG89	Adenocarcinoma Duke's Stage B	Colon-Sigmoid 16	14	263
	Cln SG67	Adenocarcinoma Duke's Stage C	Colon-Sigmoid 17	18	32
	Cln SG33	Adenocarcinoma Duke's Stages C	Colon-Sigmoid 18	43	1075

- 29 -

	Cln B34	Adenocarcinoma Duke's Stage A	Colon- Rectosigmoid 19	1	56
	Cln CXGA	Adenocarcinoma Duke's Stage A	Colon-Rectum 20	95	1041
	Cln RC67	Adenocarcinoma Duke's Stage B	Colon-Rectum 21	32	207
	Cln SG98	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 22	223	2781
5	Cln C9XR	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 23	1	277
	Cln RS45	Adenocarcinoma Duke's Stage C	Colon- Rectosigmoid 24	535	513
	Cln RC89	Adenocarcinoma Duke's Stage D	Colon-Rectum 25	0	157
	Cln RC24	Adenocarcinoma Duke's Stage D	Colon-Rectum 26	232	346
	Bld 32XK		Bladder 1	2	0
	Bld 46XK		Bladder 2	0	0
	Bld 66X		Bladder 3	0	0
10	Cvx NKS54		Cervix 1	0	0
	Cvx KS52		Cervix 2	0	0
	Cvx NK24		Cervix 3	0	0
	End 10479		Endometrium 1	0	0
15	End 8911		Endometrium 2	0	0
	End 8XA		Endometrium 3	0	0
	Kid 5XD		Kidney 1	0	0
	Kid 109XD		Kidney 2	0	0
	Kid 107XD		Kidney 3	0	0
20	Kid 6XD		Kidney 4	0	0

- 30 -

	Kid 106XD	Kidney 5	0	0
	Kid 126XD	Kidney 6	0	0
5	Kid 12XD	Kidney 7	0	0
	Liv 42X	Liver 1	0	0
	Liv 15XA	Liver 2	0	0
	Liv 94XA	Liver 3	0	0
	Lng AC69	Lung 1	0	0
10	Lng BR94	Lung 2	0	0
	Lng 47XQ	Lung 3	0	0
	Lng 90X	Lung 4	0	0
	Mam 59X	Mammary Gland 1	0	0
	Mam 12X	Mammary Gland 2	0	0
15	Mam B011X	Mammary Gland 3	0	0
	Mam A06X	Mammary Gland 4	0	0
	Pan 71XL	Pancreas 1	1	0.12
	Pan 77X	Pancreas 2	0	0
20	Pan 92X	Pancreas 3	0	0
	Pan 82XP	Pancreas 4	0	0
	Pro 109XB	Prostate 1	0	0
	Pro 34B	Prostate 2	0.48	0.23
25	Pro 12B	Prostate 3	0.36	0
	Pro 23B	Prostate 4	0.33	0
	Tst 39X	Testis 1	0	7.67
	Utr 85XU	Uterus 1	0	0
30	Utr 141XO	Uterus 2	0	0
	Utr 23XU	Uterus 3	0	0

- 31 -

0=negative

In the analysis of matching samples, the higher levels of expression were in colon, showing a high degree of tissue specificity for colon tissue. Of all the samples different than colon analyzed, only one sample (the cancer sample Liver 2 with 48.6) showed an expression comparable to the mRNA expression in colon. These results confirm the tissue specificity results obtained with the panel of normal pooled samples (Table 6).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher or lower levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 7 shows the reduction of mRNA levels of Cln125 in 24 primary colon cancer tissues compared with their respective normal adjacent (colon samples #1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, and 26). There was overexpression in the cancer tissue for two of the colon matching samples tested (total of 26 colon matching samples).

Altogether, the high level of tissue specificity, plus the dramatic reduction of mRNA levels of Cln125 in the majority (92%) of the colon cancer samples in the matching pairs tested are demonstrative of Cln125 being a diagnostic marker for colon cancer.

What is claimed is:

1. A method for diagnosing the presence of colon cancer in a patient comprising:
 - (a) measuring levels of CSG in cells, tissues or bodily fluids in said patient; and
 - (b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein an increase in measured levels of CSG in said patient versus normal human control is associated with 10 the presence of colon cancer.
2. A method of diagnosing metastatic colon cancer in a patient comprising:
 - (a) identifying a patient having colon cancer that is not known to have metastasized;
 - (b) measuring CSG levels in a sample of cells, tissues, or bodily fluid from said patient for CSG; and
 - (c) comparing the measured CSG levels with levels of CSG in cell, tissue, or bodily fluid type of a normal human control, wherein an increase in measured CSG levels in the 20 patient versus the normal human control is associated with a cancer which has metastasized.
3. A method of staging colon cancer in a patient having colon cancer comprising:
 - (a) identifying a patient having colon cancer;
 - (b) measuring CSG levels in a sample of cells, tissues, or bodily fluid from said patient; and
 - (c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in measured CSG levels in said 30 patient versus the normal human control is associated with a cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

- 33 -

4. A method of monitoring colon cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having colon cancer that is not known to have metastasized;

5 (b) periodically measuring levels of CSG in samples of cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid type of a normal human control, wherein an increase in any one of the 10 periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

5. A method of monitoring the change in stage of colon cancer in a patient comprising:

15 (a) identifying a patient having colon cancer;

(b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid type of a

20 normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

25 6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1, 2 or 3.

7. An antibody against an CSG wherein said CSG comprises SEQ ID NO:1, 2 or 3.

8. A method of imaging colon cancer in a patient 30 comprising administering to the patient an antibody of claim 7.

- 34 -

9. The method of claim 8 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10. A method of treating colon cancer in a patient comprising administering to the patient an antibody of claim
5 7.

11. The method of claim 10 wherein the antibody is conjugated to a cytotoxic agent.

SEQUENCE LISTING

<110> Sun, Yongming
Recipon, Herve
Macina, Roberto A
DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
IMAGING AND TREATING COLON CANCER

<130> DEX-0039

<140>

<141>

<150> 60/095,231
<151> 1998-08-04

<160> 3

<170> PatentIn Ver. 2.0

<210> 1
<211> 1710
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (1704)

<400> 1
ggcagagcga ctgaagacca gcctgcagaa ggctctggag gaagagctgg agcaaagacc 60
tcgacttggaa ggccttcagc caggccagga cagatggagg gggcctgcta tggaaaggcc 120
gctccctatg gaggcggcac gctatctggaa gccggggatc cttccagaac agccccacca 180
gaggacccta gaggcacagcc tcccaccatc cccaaaggccc ctgccacgcc acaccagtgc 240
ccgagaacca agtgccctta ctctgcctcc tccaaaggccg tcctttccc ccgaggaccc 300
agagagggac gaggaagtgc tgaaccatgt cctaaggggac attgagctgt tcatggaaa 360
gctggagaag gcccaggcaa agaccagcg gaagaagaaa ttggggaaaa aaaacaaggaa 420
ccaggagggt ctcacccagg cacagtacat tgactgcttc cagaagatca agtacagctt 480
caacccctcg ggaaggctgg ccacctggct gaaggagaca agtgccttc agctcgtaca 540
catcccttcc aagtccctga acttcattcc ggcagggtgc cctgaggctg gccttagcagc 600
ccaagtgtac tcacccctcc tcacccctaa agctatcaac ctgtctacatg cctgtctaa 660
cccaacctgag agtaaccttt ggatgggtt gggcccgacc tggaccacta gcccggccga 720
ctggacaggc gatgagcccc tgccttacca accacatc tcagatgact ggcaacttcc 780
agagccctcc agccaagcac ccttaggata ccaggaccct gttcccttc ggcggggaaag 840
tcataggtta gggagcacct cacacttcc tcaggagaag acacacaacc atgaccctca 900
gcctggggac cccaaactcca ggcctccag ccccaaacct gcccagccag ccctgaaaat 960

gcaagtcttg tacgagttt aagctaggaa cccacggaa ctgactgtgg tccagggaga 1020
 gaagctggag gttctggacc acagcaagcg gtggtgctg gtgaagaatg aggcgggacg 1080
 gagcggctac attccaagca acatccttga gcccctacag cgggggaccc ctgggaccca 1140
 gggccagtca ccctctcggt ttccaatgct tcgacttagc tcgaggcctg aagaggtcac 1200
 agactggctg caggcagaga acttctccac tgccacggtg aggacactt ggtccctgac 1260
 ggggagccag ctacttcgca taagacctgg ggagctacag atgctatgtc cacaggaggc 1320
 cccacgaatc ctgtcccgcc tggaggtgt cagaaggatg ctggggataa gccccttaggc 1380
 accagcttag acacctccaa gaaccaggcc cegctgatgc aagatggcag atctgatacc 1440
 cattagagcc ccgagaattc ctcttcgga tcccaagttt cagcaaacc cacaacccag 1500
 ctcacacagc aaaaacaatg gacaggccca gagggctgaag caaacagtgt cccttctggc 1560
 tgtgttggag cctcccccagt aaccacctat ttatttacc tctttcccaa acctggagca 1620
 tttatgccta ggcttgtcaa gaatctgttc agtccctctc cttctcaata aaagcatctt 1680
 caagcttgc aaaaaaaaaa taangataaa 1710

<210> 2
 <211> 1109
 <212> DNA
 <213> Homo sapiens

<400> 2
 gggAACCCACCTTCTGTGAGATGACAGCAATTATA GCAAGGACCTGCCAGGCTGT CGAAAAGATT 60
 CCAGAATAAAACTTTGCCAGTGGAAGTACCTAGTAAACGGCTTAAGATGCCACTTCTT 120
 CTCATGTCCCAGGCTTGAGGCTCTGTGTCGCCATCCTTGCGAGAAGTCA GCTCCAGCAC 180
 CATGAAGGGCATTCTCGTTCTGGTATCAC TGCACTGCTTGTGCAGCTG TGAATCTCT 300
 GAGCTGCCTGAGTGTAACTCTGTGTC AACAGCATGCTCTGAATG 360
 TCCCTCACATGCCAACACCA GCTGTATCAGCTCTCAGCCAGCTCCTCTC TAGAGACACC 420
 AGTCAGATTAATCAGAGTCAGGAGAACAGCTGAGGAGACACACAT 480
 TACAGCCTTCAGTGTCCACGTGTCTGTCAGAACACTTTCATTTGTAAGCCAGTGTGCT 540
 CCAAGGAAAGGAATGCGAACACCA TGCCCTGGACCTCCCTGAGAACAGTGTGTC 600
 CAGCAACCGCAAGTGCCTGCTTGTATGAACTTAATGGAACCTCCTGTC GTGGGAAGGCC 660
 CTGGAAATGCTATGAAGAACAGTGTGTCTTCTCTAGTTGCAAGACTTAAGAACATGACAT 720
 TGAGTCTAAGAGTCCTGTGCTGAAAGGCTGTTCCAACGTCAGAACGCCACCTGTCAAGT 780
 CCTGTCTGGTGGAAACAGCTCTTGAGTCATCTTCAGAACAGTTTGTGTGCAAA 840
 TGTAAACAGCTTAACCCCCCGTCGFCACCAACCACCTCCACAAACGTGGCTCCAAAGC 900
 TTCCCTCTACCTCTGGCCCTTGCCAGCCTCTCTGGGGACTGCTGCCTGAGGTCC 960
 TGGGCTGCACTTGCCCAAGACCCATTCTGCTCTGAGGTCCAGAGCACCCCTG 1020
 CGGTGCTGACACCTCTTCCTGCTGCCCCATTCTGAGGTTAAC TGCCAGTAAAGTGGAGTC 1080
 CAGGTCTCCA GGCAATGCCAGACAGCTGCC 1109

<210> 3
 <211> 1141
 <212> DNA
 <213> Homo sapiens

<400> 3
 CAGAGAAAGAGAACATAGAGGTGCCAAA GGAACAAAGA CATAATGATGTCATCCAAGC 60
 CAACAAGCCA TGCTGAAGTAATGAAACCA TACCAACCCCTTACCAAGCTTTAAGC 120

tggctcctgg atttcaacag cctctgggtt caatcaactt agaaaaccaa gctcagggtg 180
ctcagcgtgc tcagccctat ggcacatcacat ctccggaaat ctttgcttagc agtcaaccgg 240
gtcaaggaaa tatacaaataatg ataaatccaa gtgtggaaac agcagtaatg aactttaaag 300
aagaagcaaa ggcacttaggg gtgatccaga tcatgggtgg attgatgcac attggtttg 360
gaattttttt gtgttaata tccttcctt ttagagaagt attaggtttt gcctctactg 420
ctgttattgg tggataccca ttctgggtg gccttcttt tattatctct ggctctct 480
ctgtgtcagc atccaaggag ctttcccggtt gtctggtaa aggccgcctg ggaatgaaca 540
ttgttagttc tatcttggcc ttcatggag tgattctgct gctgggtggat atgtcatca 600
atggggtagc tggccaagac tactggcccg tgcttctgg aaaaggcatt tcagccacgc 660
tgatgatctt ctccctctt gagttctcg tagttgtgc cacagcccat tttgccaacc 720
aagcaaacac cacaaccaat atgtctgtcc tggatttcc aaatatgtat gaaagcaacc 780
ctgtgacacc agcgtctct tcagctccctc ccagatgcaa caactactca gctaatgccc 840
ctaaatagta aaagaaaaaag gggtatcagt ctaatctcat ggagaaaaaac tacttgcaaa 900
aacttcttaa gaagatgtct ttatttgtct acaatgattt ctatgtttttaaaaactgtgt 960
ttgagatttg ttttttagttt ggtcgctaat gatggctgta tctcccttca ctgtctttc 1020
ctacattacc actactacat gctggcaaag gtgaaggatc agaggactga aaaatgattc 1080
tgcaactctc taaaagtttag aatgtttctt gttcatatta cttttcctt aataaaatgt 1140
c

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/16357

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 51/00, 39/395; C12Q 1/00, 1/68; G01N 33/53; C07K 1/00, 16/00
US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/1.49, 130.1, 141.1, 178.1; 435/4, 6, 7.1; 530/350, 387.1, 387.9, 388.1, 388.8, 389.7, 391.1, 391.3, 391

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS, CANCERLIT, BIOSIS, EMBASE, WPIDS, GENBANK

search terms: colon specific gene, diagnosis, colon cancer, diagnosis, treatment, staging, antibody, imaging CSG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,733,748 (YU et al) 31 March 1998, see entire document especially abstract, col 2; lines 24-42, col 3, lines 1-6,	1, 2 4, 5
-----		-----
Y		3
P, X	US 5,861,494 (SOPPET et al) 19 January 1999, see entire document, especially abstract and col 2, lines 19-65	1, 2, 4, 5
-----		-----
P, Y		3

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
E earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*&*	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 SEPTEMBER 1999

Date of mailing of the international search report

09 NOV 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized Officer

SUSAN UNGAR

Faxsimile No. (703) 305-3230

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US99/16357**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/16357

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/1.49, 130.1, 141.1, 178.1; 435/4, 6, 7.1; 530/350, 387.1, 387.9, 388.1, 388.8, 389.7, 391.1, 391.3, 391

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1, 2 AND 6, drawn to a method for diagnosing the presence of colon cancer in a patient.

Group II, claim(s) 3 and 6, drawn to a method of staging colon cancer in a patient.

Group III, claim(s) 4, 5 and 6, drawn to a method of monitoring colon cancer in a patient.

Group IV, claim(s) 7, drawn to an antibody against a CSG.

Group V, claim(s) 8-9, drawn to a method of imaging colon cancer in a patient.

Group VI, claim(s) 10-11, drawn to a method of treating colon cancer in a patient.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking groups I-VI appears to be that they all relate to CSG which is a colon specific gene.

However, US Patent No. 5,733,748 specifically teaches colon specific genes and polypeptides encoded by those genes as well as methods of diagnosing colon cancer by measuring the gene products and antibodies specific to the colon specific gene polypeptides (see abstract).

Therefore the technical feature linking the inventions of groups I-VI does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

The special technical feature of Group I is considered to be a method for diagnosing the presence of colon cancer in a patient.

The special technical feature of Group II is considered to be a method of staging colon cancer in a patient.

The special technical feature of Group III is considered to be a method of monitoring colon cancer in a patient.

The special technical feature of Group IV is considered to be an antibody against CSG

The special technical feature of Group V is considered to be a method of imaging colon cancer in a patient.

The special technical feature of Group VI is considered to be a method of treating colon cancer.